Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 20, 2025Open Access

Efficacy and safety of durvalumab and gemcitabine-based chemotherapy combined with or without lenvatinib in advanced biliary tract cancer: A retrospective real-world study

View Full Paper
Ask AI
Bookmark
Share

Authors

QDQi DingYWY WangGWGang Wang

Discussion

Loading...

Member takes

Overview

Retrospective study assesses how durvalumab with gemcitabine and lenvatinib affects patient outcomes in biliary tract cancer, suggesting safety and efficacy.

Key Points

  • Patients treated with durvalumab and chemotherapy showed a median overall survival of 11.82 months, indicating promising results.
  • The addition of lenvatinib improved progression-free survival to 7.42 months compared to 4.98 months without it.
  • Among patients receiving lenvatinib, the objective response rate was notably higher at 57.1%, compared to 31.2% without lenvatinib.
  • The combination therapy maintained a safety profile, as adverse events were consistent regardless of lenvatinib addition.

Cite This Study

Ding et al. (2025) studied this question.

synapsesocial.com/papers/68af408ecf1dd9ea359ec2f4https://doi.org/10.21203/rs.3.rs-7101973/v1
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Comparative efficacy and safety of targeted therapeutics or immunotherapy agents combined with chemotherapy as first-line treatment for advanced biliary tract cancer: a systematic review and network meta-analysis2025
  2. 2Exploring the Impact of first-line Durvalumab plus chemotherapy on advanced biliary tract cancer: A Systematic Review and Meta-Analysis2025
  3. 3UK Real-World Evidence of Using Durvalumab Plus Cisplatin and Gemcitabine in Advanced Biliary Tract Cancer via an Early Access Scheme2025
  4. 4Role of the immunotherapy in the treatment of biliary tract cancers: Review of current clinical trials and retrospective analysis2025
  5. 5Nab-paclitaxel-based chemotherapy with or without anti-PD-(L)1 immunotherapy as a second-line treatment for advanced biliary tract cancer: a real-world retrospective study2025